124 related articles for article (PubMed ID: 11726220)
1. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency.
Razvi S; Schneider L; Jonas MM; Cunningham-Rundles C
Clin Immunol; 2001 Dec; 101(3):284-8. PubMed ID: 11726220
[TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
3. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
6. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
7. Evolution of hepatitis C virus quasispecies during therapy with IL2 combinated to alpha interferon and ribavirin.
Boulestin A; Sandres-Saune K; Alric L; Pipy B; Dubois M; Vinel JP; Izopet J
Antivir Ther; 2005; 10(4):499-504. PubMed ID: 16038475
[TBL] [Abstract][Full Text] [Related]
8. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
Jain AB; Eghtesad B; Venkataramanan R; Fontes PA; Kashyap R; Dvorchik I; Shakil AO; Kingery L; Fung JJ
Liver Transpl; 2002 Nov; 8(11):1007-13. PubMed ID: 12424713
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.
Honda T; Katano Y; Urano F; Murayama M; Hayashi K; Ishigami M; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
J Gastroenterol Hepatol; 2007 Jul; 22(7):989-95. PubMed ID: 17608843
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with natural interferon (alfaferone) in clinical practice--our experience].
Dybowska D; Halota W
Przegl Epidemiol; 2007; 61(1):17-22. PubMed ID: 17702434
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up after successful interferon therapy of acute hepatitis C.
Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
[TBL] [Abstract][Full Text] [Related]
12. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Bonny C; Fontaine H; Poynard T; Hézode C; Larrey D; Marcellin P; Bourlière M; Bronowicki JP; Merle P; Zarski JP; Sapey T; Guillemard C; Ughetto S; Henquell C; Nicolas C; Roche C; Randl K; Bommelaer G; Abergel A
Aliment Pharmacol Ther; 2006 Aug; 24(4):593-600. PubMed ID: 16907892
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatitis C virus infection in thalassemia.
Butensky E; Pakbaz Z; Foote D; Walters MC; Vichinsky EP; Harmatz P
Ann N Y Acad Sci; 2005; 1054():290-9. PubMed ID: 16339677
[TBL] [Abstract][Full Text] [Related]
16. [Therapy with interferon plus ribavirin in hemodialysis patient with PCR-positive viral hepatitis C].
Arambarri M; Fernández Lucas M; Echarri R; Teruel JL; Alarcón C; Merino JL; Ortuño J
Nefrologia; 2004; 24 Suppl 3():39-42. PubMed ID: 15219067
[TBL] [Abstract][Full Text] [Related]
17. High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.
Cheng PN; Jen CM; Young KC; Chen CY; Lu SN; Wang CS; Chang TT
Hepatogastroenterology; 2003; 50(50):449-52. PubMed ID: 12749244
[TBL] [Abstract][Full Text] [Related]
18. Cryofibrinogen in patients with hepatitis C virus infection.
Delluc A; Saadoun D; Ghillani-Dalbin P; Sene D; Piette JC; Cacoub P
Am J Med; 2008 Jul; 121(7):624-31. PubMed ID: 18589059
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with hepatitis C virus on the waiting list.
Everson GT
Liver Transpl; 2003 Nov; 9(11):S90-4. PubMed ID: 14586902
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of chronic hepatitis C treatment in hemophilic patients.
Husa P; Roznovsky L; Smejkal P; Husova L; Penka M; Dite P
Hepatogastroenterology; 2005; 52(65):1541-4. PubMed ID: 16201114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
